Abatacept Reduces Rheumatoid Arthritis Progression in Seropositive Palindromic Rheumatism

Intervening in the Pre-Rheumatoid Arthritis Continuum

Rheumatoid arthritis (RA) remains a significant cause of joint destruction and disability, affecting a substantial portion of the population [1, 2]. A critical window for intervention exists in the preclinical phase, particularly for individuals with palindromic rheumatism, a condition marked by recurrent, self-resolving inflammatory joint attacks. Those who are also positive for rheumatoid factor and/or anti-citrullinated protein antibodies face a high risk of progressing to persistent RA [3, 4]. While this seropositive status helps identify at-risk patients, effective strategies to halt or delay this progression have been elusive [5, 6, 7, 8]. A recent trial now provides direct evidence comparing two potential interventions for this specific patient population [9].

Study Design and Primary Objective

To address this clinical challenge, researchers conducted a randomized, open-label, multicenter trial to determine if early treatment with abatacept could prevent or delay the onset of RA. The study enrolled individuals with seropositive palindromic rheumatism and assigned them to one of two treatment arms for two years. The experimental group (n = 34) received abatacept, a T-cell co-stimulation modulator, administered as 125 mg subcutaneous injections weekly for the first year and every two weeks for the second. The comparator group (n = 36) received oral hydroxychloroquine at a standard dose of 5 mg per kilogram per day. The primary objective was to measure the proportion of participants in each group who developed persistent arthritis that fulfilled the 2010 American College of Rheumatology and European Alliance of Associations for Rheumatology classification criteria for RA over the 24-month follow-up period.

Abatacept Significantly Lowers RA Progression Risk

The study met its primary endpoint, demonstrating a substantial reduction in RA development with abatacept. The primary analysis, which used a conservative statistical method that assumes participants who dropped out would have progressed to RA (a modified full analysis set with failure imputation), found that only 7 of 34 participants (20.6%) treated with abatacept developed RA over 24 months, compared with 18 of 36 participants (50.0%) treated with hydroxychloroquine (P = 0.010). This represents an absolute risk difference of 29.4% (95% confidence interval 8.2 to 50.7), underscoring a clinically meaningful benefit. These results were supported by a separate analysis that included only data from participants who completed the study, which also showed a significant difference in favor of abatacept (10.0% vs. 35.7%; P = 0.019). Furthermore, abatacept not only reduced the incidence of RA but also significantly delayed its onset. The time to progression to RA was longer in the abatacept group, with a hazard ratio of 0.27 (95% confidence interval 0.07 to 0.96; log-rank test P = 0.0299).

Impact on Symptoms and Tolerability

Beyond preventing progression to RA, the trial also evaluated the impact of treatment on the clinical features of palindromic rheumatism itself. Compared to hydroxychloroquine, abatacept was associated with a reduced intensity of joint attacks and a higher frequency of symptom remission. This suggests that in addition to its disease-modifying effects, abatacept provides superior symptomatic control for patients. Interestingly, the study found no significant difference in the frequency of attacks between the two drugs, indicating that while abatacept lessened the severity of episodes, it did not change how often they occurred. From an immunological standpoint, the researchers observed no relevant differences in the evolution of antimodified peptide or protein antibody titers between the treatment arms. This finding suggests the clinical benefits of abatacept in this context may be driven by mechanisms other than the suppression of these specific autoantibody levels. Importantly, both treatments were well tolerated, with no major differences in adverse events reported.

Clinical Implications and Future Directions

These findings provide clear, actionable evidence for clinicians managing patients with seropositive palindromic rheumatism. The trial demonstrates that a two-year course of abatacept, when compared with hydroxychloroquine, can significantly alter the natural history of the disease in this high-risk group. The observed reduction in RA incidence from 50.0% in the hydroxychloroquine group to 20.6% in the abatacept group (risk difference 29.4%, 95% CI 8.2 to 50.7) supports considering abatacept as a primary intervention to prevent the development of chronic, destructive arthritis. In addition to this preventative effect, the associated reduction in joint attack intensity and higher rates of remission offer patients improved quality of life during the treatment period. Given that both drugs were well tolerated, these data strengthen the rationale for early, targeted immunomodulation in the pre-RA continuum. The full trial details are registered on ClinicalTrials.gov (NCT03669367) and EudraCT (2017-004543-20), providing transparency for clinical decision-making.

References

1. Kowalski E, Qian G, Vanni KM, Sparks JA. A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of Rheumatoid Arthritis. Frontiers in Immunology. 2022. doi:10.3389/fimmu.2022.890996

2. Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C. Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Frontiers in Immunology. 2021. doi:10.3389/fimmu.2021.686155

3. Frade-Sosa B, Morlà R, Tobalina L, Pérez-García C, Haro I, Sanmartí R. AB0196 ABATACEPT VERSUS HYDROXYCHLOROQUINE IN PALINDROMIC RHEUMATISM: A MULTICENTER RANDOMIZED CLINICAL TRIAL (PALABA STUDY): TRIAL DESIGN AND PATIENTS CHARACTERISTICS. Annals of the Rheumatic Diseases. 2022. doi:10.1136/annrheumdis-2022-eular.3316

4. Sanmartí R, Frade‐Sosa B, Morlà R, et al. Palindromic Rheumatism: Just a Pre-rheumatoid Stage or Something Else?. Frontiers in Medicine. 2021. doi:10.3389/fmed.2021.657983

5. Qureshi S, Adas MA, Cope PJ, et al. Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis. RMD Open. 2026. doi:10.1136/rmdopen-2025-006368

6. Deane KD. Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention. Current Opinion in Rheumatology. 2024. doi:10.1097/bor.0000000000001013

7. Skydel JJ, Hsiao B. Frontiers in Rheumatoid Arthritis: Emerging Research and Unmet Needs in Pharmacologic Management. Pharmaceuticals. 2026. doi:10.3390/ph19020218

8. Boeren AMP, Oei E, Mil AHMVDH. The value of MRI for detecting subclinical joint inflammation in clinically suspect arthralgia. RMD Open. 2022. doi:10.1136/rmdopen-2021-002128

9. Sanmarti R, Pérez-García C, de-Toro FJ, et al. Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.. Nature medicine. 2026. doi:10.1038/s41591-026-04395-6